



## Viatriis Statement Regarding the Closing of Global Research and Development Collaboration with Idorsia

March 18, 2024

**PITTSBURGH, March 18, 2024** – As previously disclosed on February 28, 2024, Viatriis Inc. entered into agreements for a global research and development collaboration with Idorsia Ltd (SIX: IDIA). The transaction closed on March 15, 2024. Please refer to Viatriis' Annual Report on Form 10-K for the year ended December 31, 2023, filed with the United States Securities and Exchange Commission, for more information regarding the transaction.

### R&D Event

Viatriis will hold an R&D Event on March 27, 2024, from 10 a.m. to noon ET, in New York City.

The event will include presentations from Viatriis executives discussing the collaboration with Idorsia and other elements of the Company's pipeline, as well as presentations from two expert thought leaders. The presenters will be available to answer questions at the end of the presentations.

Expert thought leaders presenting at the event are:

- Dr. Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, a top expert in cardiovascular medicine and interventional cardiology, is the Director of Mount Sinai Fuster Heart Hospital. Dr. Bhatt is highly recognized for his significant breakthroughs in the field of cardiology, including interventional cardiology, heart disease prevention, vascular medicine, and heart failure.
- Dr. Anca Askanase, MD, founder and clinical director of Columbia University's new Lupus Center and the Director of Rheumatology Clinical Trials. Dr. Askanase is an internationally renowned clinician, diagnostician and researcher with more than 15 years specializing in complex SLE. Dr. Askanase trained as a rheumatologist at New York University where she remained for more than 15 years on faculty, directing clinical trials, training fellows and residents, and treating challenging cases of SLE at NYU's prestigious hospitals.

Interested parties will be able to access a live webcast of the event at [investor.viatriis.com](https://investor.viatriis.com). An archived version also will be available following the live event and can be accessed at the same location for a limited time.

### About Viatriis

[Viatriis Inc.](https://www.viatriis.com) (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatriis. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at [viatriis.com](https://www.viatriis.com) and [investor.viatriis.com](https://investor.viatriis.com), and connect with us on [LinkedIn](https://www.linkedin.com/company/viatriis), [Instagram](https://www.instagram.com/viatriis), [YouTube](https://www.youtube.com/viatriis) and [X](https://twitter.com/viatriis) (formerly Twitter).

### Contacts:

#### MEDIA

+1.724.514.1968  
[Communications@viatriis.com](mailto:Communications@viatriis.com)

Jennifer Mauer  
[Jennifer.Mauer@viatriis.com](mailto:Jennifer.Mauer@viatriis.com)

Matt Klein  
[Matthew.Klein@viatriis.com](mailto:Matthew.Klein@viatriis.com)

#### INVESTORS

Bill Szablewski  
+1.412.707.2866  
[InvestorRelations@viatriis.com](mailto:InvestorRelations@viatriis.com)  
[William.Szablewski@viatriis.com](mailto:William.Szablewski@viatriis.com)

###